Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
HNY to all invested here and yes I too feel it’s a total no brainer here to vote for the proposals put forward given virtually all of us had written this off ,(in our minds at least) so we have to be grateful for something I guess
I also totally get the negative vibes about Duncan p & Alex S as whilst they’re great scientists, business gurus they most certainly ain’t , so something needs to change on that score for sure
That said though both those 2 put £750k into the last fundraise and are now putting forward another £150k each thereby giving them another 2.5 million shares each if my maths are right
So My own take is on that alone ,surely no one in their right mind would be stupid enough to then put forward a further £150k each in here if they didn’t know that something was clearly imminent or at least in the offing ?
It’s also coincidence now with hindsight of course that that big trade trf took place shortly after armistice took control on the 27/10 and in some ways if they had offered the full package to clear everything including w/c for a further 12mths is it any surprise really , that they didn’t want anyone else involved at this stage, as I’m not sure why they would and even more so if their due diligence had proven successful , otherwise why have they it ffs is what my first impression would be .
On that latter point, I’d defo have no issues adding here but firstly I’d need to see some tangible evidence either with positive progressive scientific news or definitive milestone payments being received ,b4 I did , as we must be due something on that score pretty soon .
Tbh after that friday Rns I’m just so grateful we might get something after months of not knowing so here’s wishing all invested here all the very best for a healthy &prosperous new year to all 4d’ers everywhere GLA
Yes fair point mate , but I was in fact trying to say this company had all the makings of being something special and it’s just sad to see it , in the state it is at the moment .
There’s nothing in that Rns today which doesn’t imply if this does not work out to be viable it will be such a truly sad state of affairs as the science is undoubtedly proving they are most definitely onto something here . Sigh , but u never know the time it’s taking is hopefully positive news for us pi’s .if it was 80 million shares swapped /traded whatever it was wouldn’t that be about the amount monetary wise as to how much OF are supposedly outstanding or is that just coincidence ? Anyway GLA
I know it’s only another glimmer but I was just musing the current dollar/sterling exchange rate which is now around 1.10 where it was around 1.24 at the time of administration & from memory I think we had 7.4 million dollars on deposit( or just under £6 million) at the time , but at current exchange rates it’s more like £6.8 million now which is a significant jump if it still remains on deposit of course, and not been paid out as yet. At £650 an hour for interpath it won’t do us any harm 4 sure . GLA
That’s a fair point shear class but it was written in 2018 and as far as I’m aware is based on a nickel price between £14-16k a ton so with what’s coming it’s a fair bet it will be a lot higher than that even over the first 4 years or I for one have dropped a big Graeme Pollock here .
I’m like most on here not holding out a great deal of faith in truth but I’d like to think that today gives us a glimmer potentially .
That said the wording may be exactly as Mig stated earlier & yes I accept fully at £650 an hour the administrators are coining it in .
Looking at what’s available here with 4d I still can’t believe with the dollar strength right now that it surely offers the likes of Merck & others a golden opportunity to pick this up for a fraction of what its truly worth , or was .
Look we are where we are , that’s the bottom line and whilst hope is no strategy that final paragraph offers me some faint hope I guess . GLA
BoonCo ur spot on mate , look it wasn’t a great presentation we all agree on that, but DP did say some positive things re the Vaccine programme and he also emphasised the main focus of 4d right now is on the 0518 tie up with keytruda the worlds best selling drug … and he distinctly said that he was hopeful that the results in the NSCLC trial were going to be very similar to those acquired in the RCC trial where the primary endpoint was met early , and if it did then that would be a huge inflection point on a number of fronts
Lest we forget this is a company with numerous collaborations on the go not just with the likes of Merckx, & Pfizer but MD Anderson cancer centre ,the Imperial College , the MJ Fox foundation so for me the idea that Oxford finance are seriously considering foreclosing on a 5 million dollar advance when a milestone payment could drop at any point is beyond my comprehension tbh but maybe that’s just my confirmation bias kicking in , I get that , but i still believe there’s more chance of this suspension being good news than bad , but that’s just my take on it as always GLA
If ur invested here like me and u have a decent holding with the share price at 15-16p , a market cap of only 28 million , and the possibility of an immediate buyout / collaboration , or whatever being no more than slim at this juncture , then the big Q right now whether we agree with it or not , is to decide as to whether we do want to only allow the company to issue just 40% of the share capital , which will raise peanuts as SR points out …or 100% of the share capital which would at least give us half a chance bearing in mind ideally ,we somehow need to raise 45 million by the end of the year .
So As disappointed as I am at present ,I still believe in the science & I’m also convinced DP &JD think likewise , along with the company pipeline , products & people.
I’m also pretty convinced that once the Agm & the key resolutions are passed (assuming they are) ….that news flow will resume soon after ,as the company & us shareholders both desperately need it much higher than the current -hit show.
The other issue of course is that they can not surely want to be raising placing funds at these bat **** crazy levels .
This I’m sure is another reason why DP mentioned yesterday as to why the $150 million option they filed in the US earlier this year as I recall was done so in anticipation of raising cash but clearly at a much much higher price than it is today grrrrrr .
Anyway GLA
Another interesting article about Merckx looking at acquiring Seagen for a potentially a pretty large outlay
https://www.fiercepharma.com/pharma/merck-eyes-28b-purchase-seagen-amid-quest-diversify-star-cancer-drug-keytruda-wsj
More relevant to us however are these pieces in the article which implies to me at least that 4d have to be on the radar if we continue to build on the results we have had so far .
“For Merck, it’s under investor pressure to diversify from the forever growing Keytruda, which contributed 35%, or $17.2 billion, to Merck’s total sales in 2021.
The company did make some smaller purchases and one relatively large acquisition last year, shelling out $11.5 billion to take in Acceleron Pharma.
Recently, at the ongoing BIO 2022, Merck’s Jannie Oosthuizen, head of U.S. Human Health, told Fierce Biotech that the company is looking at deals where it can “add significant value to the system.”
“It really does continue to be broad, focused cutting-edge science that is innovative, that will produce value, and that will really help to build out the pipeline for the future,” Oosthuizen said.
(Sound familiar ? )
“A lot of it has been done in oncology. Clearly, that's where we focused a lot over the last few years. We continue to do that.”
In the meantime, I just hope we get some guidance tomoz that’s actually meaningful . GLA & come on 4d
Some great work here on the Q&As so hats off to all contributors & thanks for ur input fellas
Just read this article about top performing pharma companies in the U S for 2021 and both Pfizer and Merckx right up there in the top 5 . There is also a glowing summary on the merits & huge revenue generating beast that their keytruda drug has become for Merckx & I hadn’t realised that their coffers had been boosted by a $ 9 billion dollar cash windfall from the “Organon” separation last year.
To think they had revenue in 2021 of $47 billion dollars and yet they’re still here with 4d …3 years down the line …so surely that must say something give us all real hope that one of these days something will come to fruition very soon . Can but hope GLA
https://www.fiercepharma.com/special-reports/top-10-most-profitable-pharma-companies-2021
I reckon we need Taunton boy to start buying in again if he’s still with us ,and any other members of the Somerset massive .
I added yesterday but typically got my timing wrong yet again doh ! …altho 30p is still a crazy price imho .
Finally I see the April presentation for anticipated milestones remains unchanged so from next week we are only a couple of weeks from the end of Q2 .
Furthermore , John Doyle the CFO will have been in situ 6months so I’d like to think he’s earned his corn over that period & something will be announced anytime soon on the financing Q .
ANTICIPATED MILESTONES AND OBJECTIVES FOR 2022
Q2 2022
• First patient dosing in Phase II study of MRx0518 & Bavencio® in urothelial carcinoma
• Complete enrollment of Phase I study of MRx0518 in pancreatic cancer
• Present data from Part A of Phase I/II study of MRx-4DP0004 in Asthma at ATS conference (May 2022)
2H 2022
• Commence Part B of Phase I/II trial of MRx-4DP0004 in Asthma
• Commence Phase I trial of MRx0005 and MRx0029 in people with Parkinson’s disease
• Provide update and guidance on Blautix® in patients with irritable bowel syndrome (IBS)
• Provide update on next steps for MRx0518 & Keytruda® combination in Renal Cell Carcinoma (RCC)
Top post that MHB ,as u rightly say first and foremost unlocking that door to the Oxford finance would be huge step forward here & the 1 in 10 target based on what we know already must be a pretty decent possibility & with future funding worries averted this should see a major re rate pretty soon after.
As frustrating as the shareprice is for most Long term holders at the minute , the reality is , if the right news drops here, which it might at any time , it may just catch a lot of people out big time . Time will tell as always .Come on 4d . GLA
Morning porky I’m as keen as u are in hoping we get an update on something very soon but I’m not sure it’s going to be anything on Blautix just yet , as in the April presentation it’s scheduled for H2 so I’d be surprised if it came any earlier myself , but plenty of other things bubbling away that could materialise hopefully .
ANTICIPATED MILESTONES AND OBJECTIVES FOR 2022
Q2 2022
• First patient dosing in Phase II study of MRx0518 & Bavencio® in urothelial carcinoma
• Complete enrollment of Phase I study of MRx0518 in pancreatic cancer
• Present data from Part A of Phase I/II study of MRx-4DP0004 in Asthma at ATS conference (May 2022)
2H 2022
• Commence Part B of Phase I/II trial of MRx-4DP0004 in Asthma
• Commence Phase I trial of MRx0005 and MRx0029 in people with Parkinson’s disease
• Provide update and guidance on Blautix® in patients with irritable bowel syndrome (IBS)
• Provide update on next steps for MRx0518 & Keytruda® combination in Renal Cell Carcinoma (RCC)
At the time of the vaccine collaboration with MSD back in Oct 19 Daria Hazuda, Chief Scientific Officer of MSD said this
“A key element of our focus in the Exploratory Science Center is the evaluation of emerging new areas of biology that have the potential to offer major beneficial impact to human health.
By applying 4D's MicroRx® technology we hope to gain meaningful insights into the role for the host microbiome in modulating the immune response and ultimately protection conferred by vaccines."
So 3 years on they’ve seen a pretty much clean bill of health for both safety & tolerability on every aspect of the 4D MicroRx platform & not only that but some very significant inroads in meeting some pretty impressive endpoints too on virtually all areas 4d has targeted to date & more specifically in cohorts with one of their own best selling drugs Keytruda
Under the terms of the agreement with MSD , 4D's proprietary MicroRx® platform will be paired with their own expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications.
4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration.
In addition to an upfront cash payment,
for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration.
( so $347.5 per indication x 3 so up to $1.044,000 in total )
Additionally , if any of that happens MSD will cover all the costs to take any of them to commercial endpoint .
In the last financial statement Axel said this (and I’m pretty sure that this was ratified by Duncan in one of this years interviews where he stated that good results had continued on the vaccine collaboration into 2022)
“We continue to advance our ground-breaking collaboration with MSD in the field of vaccines.
This collaboration, which is associated with potential milestone payments totaling over $1 billion across up to three undisclosed indications, utilizes MicroRx® to discover and develop Live Biotherapeutics for vaccines.
In 2021 we continued to make good progress in this collaboration.
A quick resume then ..so bearing in mind the progress & results 4d have delivered over the 3 year period with LBPs coupled with the fact that this is precisely the kind of emerging new areas of science the MSD CSO is looking for … then I think it’s fair to say there is a pretty decent chance of MSD either taking us out completely or investing further but time will tell as always
Point being I think this will happen but that’s just my take on it and I’m defo no expert , I’m not an adviser I’m just invested here LT so Dyor & make ur own decisions . GLA
Afternoon all , just to pick up on Sangis point regarding the cash position .. look I fully accept it’s a realistic stance by people to question the financial position of the company ,
but it’s also reasonable to look a bit deeper into the detail for the purposes of balance & looking back further on the last financial update …am I missing something here as …the chairman says this
“We continue to advance our ground-breaking collaboration with MSD in the field of vaccines. This collaboration, which is associated with potential milestone payments totaling over $1 billion across up to three undisclosed indications, utilizes MicroRx® to discover and develop Live Biotherapeutics for vaccines.
In 2021 we continued to make good progress in this collaboration.
Point being, we may be pretty close to one of these given we are into our 4th year of collaboration with MSD , they’re still here & tbf we’ve recently published some pretty half decent results and big money is very likely if that happens .
In the Financial outlook statement it then says this
“As of 31 December 2021, our cash and cash equivalents were £15.5 million.
After the year end, but before the signing of these financial statements, the Group received research and development tax credits of £3.2 million on its UK entities. “
So I’m reading that as we had £18.7 million and not £15.5 million at the time the update was published
He then says this .
“Excluding possible income from warrants, we believe that this additional cash …
the Spanish loan facility, (1million i believe )
along with existing cash and cash equivalents
…but before restrictive covenants on the Oxford loan ….
are sufficient to fund our projected operating requirements until the fourth quarter of 2022. “
(Which are the current guidelines and remain unchanged)
(So the Board feel they do have sufficient cash even with the restrictive covenant is my understanding of that .)
The Directors are continuing to explore sources of finance that are available to the Group and have a reasonable expectation that they will be able to secure sufficient cash inflows into the Group to continue its activities for not less than twelve months from the date of approval of these accounts.
The usual caveats are then applied , so yes a placing is a distinct possibility …but so are a raft of other things that could happen .
Fwiw I think the latter is far more likely myself & it is maybe wishful thinking, but after the recent updates I just can’t believe that someone like Merck is not going to step in at some point very soon and if so we won’t be at 33p
Not an advisor , defo no expert , so make ur own calls but any thoughts welcome GLA
Top post fella , well said that man !
Look I realise most people invested here will know this so I’m not trying to tell folk how to suck eggs ,but a golden rule in this game invariably is that u should never sell ur shares when it’s NT to buy on the ask …as the chances are the MM s are probably looking to fill an order , and once they have ur shares , the price will more often than not ,move up , meaning u get the bullseye classic quote of “look at what u could have won “
It’s been a long time coming this rise but in fairness I was of the view that the last few rns’ have been pretty bullish on the prospects for nuvec with the therapeutic angle , and like Leister said just recently we can’t be far off an update & if it’s half decent ,we may just be ready to start the car again at these crazy levels , so fingers crossed .GLA
just checked now I can still sell any shares at 3.23 up from 3.22 and yet I can only buy a max 1500 at 3.299 b4 it goes NT . Just popped higher now there’s a surprise
A decent buy just gone thru at 3.31
Defo something afoot here atm as just like yesterday despite any small selling pressure the bid has been lifted just like it has now where a 60k sale has prompted the mms to increase the price upwards and change the spread from 2.9-3.20 to 3-3.30 which suggests to me they know something we don’t or someone is buying despite the volumes not being that significant as yet . Either way I’m not complaining GLA
Firstly I accept it’s a totally realistic stance by people to question the financial position of the company ..perfectly reasonable
but it’s also reasonable to look a bit deeper into the detail for the purposes of balance and further on in todays report …the chairman says this
“We continue to advance our ground-breaking collaboration with MSD in the field of vaccines. This collaboration, which is associated with potential milestone payments totaling over $1 billion across up to three undisclosed indications, utilizes MicroRx® to discover and develop Live Biotherapeutics for vaccines.
In 2021 we continued to make good progress in this collaboration.
Point being, we may be pretty close to one of these given we are into our 4th year of collaboration with MSD , they’re still here and we’ve just had some pretty stunning results and big money is very likely if that happens .
In the Financial outlook statement it then says this
“As of 31 December 2021, our cash and cash equivalents were £15.5 million.
After the year end, but before the signing of these financial statements, the Group received research and development tax credits of £3.2 million on its UK entities. “
(We didn’t know that )
“Excluding possible income from warrants, we believe that this additional cash …the Spanish loan facility, along with existing cash and cash equivalents but before restrictive covenants on the Oxford loan are sufficient to fund our projected operating requirements until the fourth quarter of 2022. “
(Which are the current guidelines and remain unchanged)
The Directors are continuing to explore sources of finance that are available to the Group and have a reasonable expectation that they will be able to secure sufficient cash inflows into the Group to continue its activities for not less than twelve months from the date of approval of these accounts.
The usual caveats are then applied , so yes a placing is a possibility …but so are a raft of other things that could happen .
I think the latter is far more likely myself & it is maybe wishful thinking, but after the recent updates I just can’t believe that someone like Merck is not going to step in at some point very soon .
Cos If they did , then this won’t be at 42p that I do know. GLA